Peptides for Gaining Weight: Lean Mass, Appetite, and the Underweight Patient

Most peptide writing is aimed at losing weight, recomping a trained body, or chasing performance. The patient asking about MK-677 because she's 5'7" and 108 pounds after a year on tirzepatide doesn't show up in that literature. Neither does the 72-year-old whose grip strength dropped 30% after his prostatectomy, or the lifelong hardgainer who has logged 3,800 calories a day for six months and added four pounds.

For these patients, the things peptide articles call side effects — appetite stimulation, fluid retention, IGF-1 elevation — are the actual reason to use the drug. The evidence base for using peptides to gain weight is thinner than for losing it, but it isn't empty. The mechanisms are characterized well enough to know which compounds plausibly help, which don't, and what a realistic six- to twelve-month outcome looks like.

Ghrelin is the body's hunger signal, a 28-amino-acid peptide made mostly in the stomach that rises before meals and falls after them. Drugs that activate the ghrelin receptor (GHSR-1a) drive both appetite and pulsatile growth hormone release. For weight loss, that appetite effect is the reason MK-677 didn't reach approval. For weight gain, it's the reason to consider it.

Anamorelin is the cleanest evidence we have. It's an oral ghrelin agonist developed for cancer cachexia, tested in the ROMANA 1 and ROMANA 2 Phase 3 trials in advanced non-small-cell lung cancer. Over 12 weeks Anamorelin produced 1.0–1.4 kg of lean body mass gain over placebo, raised total body weight, and improved appetite scores. It didn't move grip strength, which is why the FDA declined to approve it in 2017. Japan approved it in 2021 for cancer cachexia under the name Adlumiz. It's still the most rigorously studied appetite-driving peptide.

MK-677 has the longest non-cancer track record. The 1998 Svensson obesity trial showed increased fat-free mass and energy expenditure. A 12-month trial in older adults raised IGF-1 40–60% and added about 1.1 kg of lean mass over two years, though strength didn't follow. For a 60-kg cachectic patient, a kilogram of lean mass plus a reliable hunger response is worth the trade. The water retention and chronic appetite that make MK-677 unpopular in cutting protocols are exactly what someone underweight needs.

The injectable ghrelin mimetics — GHRP-6, GHRP-2, Hexarelin — vary in how aggressively they push appetite versus how clean their hormonal profile is. GHRP-6 has the loudest hunger signal and the messiest receptor selectivity, with mild cortisol and prolactin bumps. GHRP-2 is gentler in both directions. Hexarelin throws the biggest GH pulse but desensitizes its own receptor on chronic dosing. Outside small endocrine studies, controlled long-term human data is essentially absent for all three.

Once appetite is handled, the question is whether the calories land as muscle or fat. Growth hormone secretagogues are the most-discussed tool, working upstream of IGF-1, the hormone that mediates most of GH's effect on protein synthesis.

CJC-1295 plus Ipamorelin is the workhorse combination. CJC-1295 extends the GHRH signal; Ipamorelin triggers a clean GH pulse without the cortisol or prolactin spikes that older ghrelin mimetics produce. Together they push GH output about three-fold above either alone. The standard clinical move is to dose at bedtime to amplify the natural nocturnal pulse.

Tesamorelin has the strongest body of clinical evidence. A 2026 meta-analysis of randomized trials confirmed lean mass preservation and visceral fat reduction in HIV-associated lipodystrophy. The HIV population isn't a perfect proxy for someone trying to gain weight from a healthy baseline, but the lean mass signal is real and the safety record across years of clinical use is the cleanest in this class. Sermorelin is the older, shorter-acting GHRH analog with a similar mechanism but less downstream IGF-1 elevation.

IGF-1 LR3 and MGF skip the pituitary and deliver the growth factor directly. They're more potent than the secretagogues and far less safe. Published human safety data is essentially absent. Hypoglycemia at higher doses is a real concern, and there's a theoretical worry about accelerating occult cancers, so they're not appropriate for older patients without a clean recent screening. Most clinicians won't prescribe them, and outside bodybuilding circles their use is uncommon.

Follistatin gets discussed because the genetic loss-of-function phenotypes — Belgian Blue cattle, the German child born with double muscle mass — are dramatic. The translation to a usable peptide therapy hasn't happened. Exogenous follistatin has weak human data, and the active programs targeting this pathway are antibody-based (apitegromab, trevogrumab, bimagrumab; covered in our myostatin-inhibitor piece), not peptide injections. For now follistatin protocols are speculative.

If you can't train consistently, you don't gain weight as muscle. BPC-157 and TB-500 fit in here as enablers. Neither builds muscle directly. BPC-157 has signals for tendon, ligament, and gut tissue repair; TB-500 (thymosin β-4) supports cell migration and angiogenesis. Both are widely used by athletes nursing injuries that would otherwise sideline them for weeks.

A 2025 systematic review of BPC-157 in orthopedic sports medicine found consistent preclinical signals and no human RCTs. Animal data is strong, mechanism is plausible, controlled human evidence is missing. The case for including either peptide in a weight-gain protocol depends on the recovery effect being real: an underweight patient who trains three times a week instead of once because their tendinopathy isn't flaring will gain more, but the chain of reasoning runs through an animal-data assumption.

The protein-and-training base matters more than any peptide here. Someone eating 0.6 g/kg/day, the median we see in GLP-1 users, won't add mass on any stack. The floor for gaining is 1.6–2.2 g/kg/day with leucine-rich sources spread across meals, plus actual progressive resistance training. Peptides multiply that foundation. They don't replace it.

The compounds discussed above, condensed.

The realistic ceiling for a non-steroid peptide stack, with adequate calories and consistent training, is roughly 1–3 kg of lean mass over six months and 2–4 kg of total weight once water and intramuscular glycogen are in. That number lines up across the older-adult, HIV, and post-cachexia trials. Nowhere near steroid range, and well below what bodybuilding forums claim.

Patient context shifts the math. The strongest case is probably post-GLP-1 rebuild: a patient who shed 10 kg of lean mass over two years on semaglutide has a body to return toward, and the same protocol that does little for a lifelong hardgainer can move them meaningfully. The most directly applicable evidence sits in older adults with sarcopenia (the MK-677 and tesamorelin data in 60+ patients), though anabolic resistance slows things and functional gains, when they happen, are more variable than the body-composition numbers suggest. Cancer cachexia is its own situation. Anamorelin's ROMANA data is the strongest signal there, lean mass and weight gains are real, functional improvement is inconsistent, and the decisions belong with an oncologist rather than a peptide protocol.

The hardgainer case is the weakest. Most published trials enrolled older or clinical populations, and extrapolating to a 22-year-old whose problem is appetite, not anabolism, is shakier than the marketing suggests. For that patient, food volume, training stimulus, and sleep are doing the work; the peptides are noise on top.

Nothing in this stack approaches the 5–10 kg of lean mass that anabolic steroids put on in a 12-week cycle. You trade real safety and reversibility for a smaller absolute number. For an underweight or recovering patient, the smaller number is usually the goal anyway: getting back to where the body was, not building a competition physique.

Body weight on a scale is a poor proxy for whether a peptide protocol is working. Water retention from MK-677 or GHRH analogs can add 1–2 kg in the first weeks that has nothing to do with lean mass, and a patient reading only the scale will misjudge whether to continue.

The minimum monitoring set is a DXA at baseline and six months. That's the only practical way to separate fat, lean mass, and bone changes; without it, you're guessing. Strength on a couple of compound lifts (squat, hip hinge, press) tracks lean mass over time better than bodyweight does — if the lifts aren't moving, the muscle probably isn't either. Quarterly fasting glucose and HbA1c catches the insulin-sensitivity blunting that MK-677 in particular can cause, which matters more than the muscle gain does. Quarterly IGF-1 confirms the secretagogue stack is doing what it claims, and persistent IGF-1 above the age-adjusted upper bound is a reason to pull dosing back.

The most common reason any of this fails has nothing to do with the labs. It's under-eating. A written protein and calorie target checked weekly does more than any of the bloodwork.

A patient who adds 3 kg of lean mass over six months on a clean secretagogue protocol with the protein and training in place has done something real. A patient who adds 8 kg in 8 weeks on a peptide stack has gained mostly water and fat, and most of it will reverse within weeks of stopping. The labs are how you tell which one happened.